Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02108808
Other study ID # PATRAS CARDIOLOGY 18
Secondary ID
Status Completed
Phase Phase 4
First received April 4, 2014
Last updated January 4, 2015
Start date April 2014
Est. completion date October 2014

Study information

Verified date January 2015
Source University of Patras
Contact n/a
Is FDA regulated No
Health authority Greece: Ethics Commiitee
Study type Interventional

Clinical Trial Summary

Fractional flow reserve (FFR) is an established invasive method for assessing the physiological significance of coronary artery stenosis. Adenosine, an important endogenous regulator of coronary blood flow during both stress and ischemia, is widely used to achieve conditions of stable hyperemia required for measurement of FFR.

Studies in healthy volunteers and in patients with acute coronary syndrome (ACS) post percutaneous coronary intervention (PCI) receiving ticagrelor revealed a differential coronary blood flow velocity response during increasing doses of adenosine compared to placebo or prasugrel treated subjects, respectively. It has also been demonstrated that patients treated with ticagrelor have increased plasma adenosine levels. Therefore, it has been hypothesized that the degree of hyperemia obtained with adenosine infusion may be greater in patients on ticagrelor than that obtained in patients taking clopidogrel or prasugrel. If this proves to be true, it would lead to a lower FFR value with possible important clinical implications in ticagrelor receiving patients in need for FFR measurement.

This is a prospective, single center, randomized study of parallel design. Consecutive ticagrelor naive patients who are referred for coronary angiography and have an angiographically moderate to severe de novo stenosis (>50% and <90% diameter by visual assessment) in at least one major epicardial coronary artery amenable to PCI are candidates for this study. Patients after informed consent will be randomized (hour 0) to receive immediately post FFR (with adenosine iintravenous infusion at 140 μg/Kg/min for a 3 minute period) either ticagrelor 180mg loading dose or prasugrel 60mg/clopidogrel 600mg loading dose (as clinically indicated). FFR examination will be repeated 2 hours post loading dose.


Recruitment information / eligibility

Status Completed
Enrollment 76
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Age 18-80 years

2. Patients subjected to clinically indicated coronary angiography with at least one 50%-90% stenosis at 1 major epicardial vessel (by visual assessment) amenable to percutaneous coronary intervention.

3. Ticagrelor naive patients

4. Written informed consent

Exclusion Criteria:

1. History of coronary artery bypass surgery

2. Acute myocardial infarction within the previous 5 days

3. Known allergy to adenosine, ticagrelor, prasugrel or clopidogrel

4. Prior intracranial hemorrhage

5. Hemodialysis or creatinine clearance < 30ml/h

6. Moderate/severe hepatic failure

7. Active bleeding, or at increased risk of bleeding

8. Left ventricular ejection fraction <40%

9. Primary myocardial or valvular disease

10. Contraindication to adenosine

11. Angiographically visible thrombus at a target lesion, extremely tortuous coronary arteries, severely calcified lesions, left main disease, anatomy suitable for coronary artery bypass surgery

12. Previous q wave myocardial infarction in the area of target vessel

13. Severe left ventricular hypertrophy

14. Severe valvular heart disease

15. Heart failure as defined by New York Heart Association class III or IV 16.Hypotension (blood pressure <90 mm Hg)

17.Significant arrhythmia (e.g. excessive premature ventricular contractions or atrial fibrillation), tachycardia (heart rate >120 beats/min), bradycardia (<50 beats/min), increased risk for bradycardia 18.Caffeine consumption or cigarette smoking within the previous 24 hours.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Ticagrelor

Prasugrel or Clopidogrel


Locations

Country Name City State
Greece Patras University Hospital Patras Achaia

Sponsors (1)

Lead Sponsor Collaborator
University of Patras

Country where clinical trial is conducted

Greece, 

Outcome

Type Measure Description Time frame Safety issue
Other Reclassification of coronary revascularization strategy at hour 2 in relation to hour 0 Number of patients who were reclassified regarding revascularization strategy at hour 2 in relation to hour 0, between the 2 treatment arms 2 hours No
Primary % relative change in steady hyperemia FFR (sFFR) Steady hyperemia FFR (sFFR) is defined as the FFR value attained during stable hyperemia (as assessed by offline visual inspection of the 3-min hemodynamic trace) (sFFR post drug - sFFR pre drug)*100/sFFR pre drug between the 2 treatment arms 2 hours No
Secondary % relative change in peak hyperemia FFR (pFFR) Peak hyperemia FFR is defined as the lowest FFR measurement during the first 60 sec of adenosine infusion (pFFR post drug - pFFR pre drug)*100/pFFR pre drug between the 2 treatment arms 2 hours No
Secondary % relative change in lowest FFR (lFFR) Lowest FFR (lFFR) is defined as the value provided by the automated FFR console (lFFR post drug - lFFR pre drug)*100/lFFR pre drug between the 2 treatment arms 2 hours No
Secondary % relative change in time to peak FFR (in seconds) (time to pFFR post drug - time to pFFR pre drug)*100/time to pFFR pre drug between the 2 treatment arms 2 hours No
Secondary % relative change in time to lowest FFR (time to lFFR post drug - time to lFFR pre drug)*100/time to lFFR pre drug between the 2 treatment arms 2 hours No
Secondary % relative change in area under the curve (AUC) of the FFR trace (AUC FFR post drug - AUC FFR pre drug)*100/AUC FFR pre drug between the 2 treatment arms 2 hours No
See also
  Status Clinical Trial Phase
Completed NCT02377310 - Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography N/A
Active, not recruiting NCT03424941 - The TransCatheter Valve and Vessels Trial N/A
Recruiting NCT03988881 - DSE vs Invasive FFR vs CT-FFR
Recruiting NCT05374733 - Coronary Physiology Peri-Transcatheter Left-sided Valvular Interventions N/A
Completed NCT04970082 - A Study to Evaluate Direct Wire Pacing (DWP) for Measuring Fractional Flow Reserve (FFR) N/A
Enrolling by invitation NCT02670005 - Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction N/A
Recruiting NCT03117218 - Correlation Between Quantitative Analysis of Coronary MRA and FFR N/A
Completed NCT03393871 - Myocardial Mass Determination by FFRct and Absolute Coronary Blood Flow
Completed NCT03163199 - TRanslesIonal Assessment of Gradients During Endovascular Therapy